RxDoctor Payments DataLook up a doctor →

Casey Long, MD

Pain Medicine · Montgomery, ALNPI 1609284751

Payments from drug & device makers

$9,037in general payments, 2019–2025

Across 563 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$717
  • Abbott$714
  • AbbVie$690
  • Amgen$628
  • Novo Nordisk$585
  • Pfizer$456
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$8,95299%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC56$717
Abbott11$714
AbbVie(2 entities)62$690
Amgen39$628
Novo Nordisk37$585
Pfizer35$456
Astellas Pharma US Inc18$377
Lilly USA, LLC25$375
Johnson & Johnson32$364
GSK23$361
Bayer17$291
AstraZeneca13$232
Merck14$230
Otsuka America Pharmaceutical, Inc.10$194
Exact Sciences12$180
Scilex Pharmaceuticals Inc.12$176
Boston Scientific14$169
Biohaven Pharmaceutical Holding Company Ltd.9$162
Takeda Pharmaceuticals U.S.A., Inc.8$146
Indivior Inc.5$141
Daiichi Sankyo Inc.8$135
Novartis8$133
Sanofi-aventis U.S. LLC7$125
Boehringer Ingelheim8$110
Mylan Specialty L.p.6$108
Sunovion Pharmaceuticals Inc.8$102
Biohaven Pharmaceuticals, Inc.5$97
Amarin Pharma, Inc.5$93
Nestle Healthcare Nutrition Inc.4$84
Collegium Pharmaceutical, Inc.4$80
Braeburn Inc.4$79
Arbor Pharmaceuticals, Inc.5$72
IBSA Pharma Inc.3$59
Clarus Therapeutics Inc.3$50
Dexcom, Inc.3$47
Biodelivery Sciences International, Inc.3$44
Sumitomo Pharma America, Inc.3$35
Ardelyx, Inc.2$35
Xeris Pharmaceuticals, Inc.2$34
Teva Pharmaceuticals USA, Inc.2$32
Idorsia Pharmaceuticals US Inc2$31
Ironwood Pharmaceuticals, Inc2$28
Forte Bio-pharma LLC1$24
Antares Pharma, Inc.1$21
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$20
Corcept Therapeutics1$18
Phathom Pharmaceuticals, Inc.1$18
Teleflex LLC1$17
Averitas Pharma Inc.1$17
Assertio Therapeutics, Inc.1$17
SK Life Science, Inc.1$16
Vanda Pharmaceuticals Inc.1$15
Esperion Therapeutics, Inc.1$15
Upsher-smith Laboratories LLC1$13
Eisai Inc.1$13
Mannkind Corporation1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,037 in reported general payments places this provider in the 85th percentile of 77 pain medicine providers in Alabama.

See all pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$50,066
Medicare patients
134
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide162$196,374
Trelegy ElliptaFluticasone/Umeclidin/Vilanter233$150,431
OzempicSemaglutide123$148,939
JardianceEmpagliflozin134$98,056
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl314$76,330
LinzessLinaclotide98$58,910
FarxigaDapagliflozin Propanediol76$55,058
EliquisApixaban69$53,773
ZubsolvBuprenorphine Hcl/Naloxone Hcl54$43,051
RexultiBrexpiprazole18$26,502
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,064$26,126
GemtesaVibegron33$23,783
TrulicityDulaglutide19$20,168
XareltoRivaroxaban21$19,905
MyrbetriqMirabegron39$17,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$375$216,542181 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$361$169,264266 claims
Novo NordiskOzempic$585$148,939123 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$110$122,949175 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$232$85,216154 claims
AbbVieLinzess$690$58,91098 claims
PfizerEliquis$456$53,77369 claims
Otsuka America Pharmaceutical, Inc.Rexulti$194$26,50218 claims
Sumitomo Pharma America, Inc.Gemtesa$35$23,78333 claims
Johnson & JohnsonXarelto$364$19,90521 claims
Astellas Pharma US IncMyrbetriq$377$17,93939 claims
Indivior Inc.Suboxone$141$15,77523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 77 pain medicine providers in Alabama.

Other pain medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →